Abivax Denies AstraZeneca Acquisition Talks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: CNBC
- Acquisition Rumor Denial: Abivax has denied media reports claiming that AstraZeneca was in talks to acquire the company, despite the report stating that AstraZeneca had exclusive access to Abivax's data since February and had until March 23 to formalize an offer.
- Stock Price Fluctuation: Following the report, Abivax's shares surged by as much as 15%, but ultimately closed about 4% higher, indicating a cautious market reaction to the acquisition rumors.
- Potential Acquisition Interest: Analysts suggest that Abivax's immunology and inflammation drug obefazimod could attract large pharmaceutical companies for acquisition, especially after its strong performance in last year's late-stage trials, enhancing its strategic value.
- Competitor Attention: In addition to AstraZeneca, Eli Lilly has also been rumored to be in talks with Abivax regarding a potential acquisition, although both companies have declined to comment, reflecting strong market interest in Abivax.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 999.840
Low
950.00
Averages
1192
High
1500
Current: 999.840
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abivax Denies AstraZeneca Acquisition Talks
- Acquisition Rumor Denial: Abivax has denied media reports claiming that AstraZeneca was in talks to acquire the company, despite the report stating that AstraZeneca had exclusive access to Abivax's data since February and had until March 23 to formalize an offer.
- Stock Price Fluctuation: Following the report, Abivax's shares surged by as much as 15%, but ultimately closed about 4% higher, indicating a cautious market reaction to the acquisition rumors.
- Potential Acquisition Interest: Analysts suggest that Abivax's immunology and inflammation drug obefazimod could attract large pharmaceutical companies for acquisition, especially after its strong performance in last year's late-stage trials, enhancing its strategic value.
- Competitor Attention: In addition to AstraZeneca, Eli Lilly has also been rumored to be in talks with Abivax regarding a potential acquisition, although both companies have declined to comment, reflecting strong market interest in Abivax.
See More
Midday Stock Highlights: Notable Movements in Multiple Stocks
- Market Decline: Mercado Libre's shares fell over 6% after JPMorgan downgraded its rating from overweight to neutral, citing increased competition and prolonged margin pressures, with the price target cut from $2,650 to $2,100, indicating concerns about future profitability.
- Cruise Industry Pressure: Shares of Royal Caribbean and Carnival dropped 5% and 6%, respectively, as oil prices surged past $100 per barrel, with fuel being one of the largest operating expenses for cruise operators, potentially impacting their profitability.
- Energy Stocks Rise: Constellation Energy and Vistra saw their shares increase by 2% following the Department of Energy's announcement of a plan to leverage existing nuclear energy infrastructure for increased power generation, highlighting the strategic importance of nuclear energy for future growth.
- Pet Health Surge: Petco Health and Wellness shares surged nearly 30% after the company indicated a potential return to sales growth, guiding for full-year revenue growth between flat and 1.5%, exceeding market expectations and reflecting confidence in its business recovery.
See More
Major Averages Decline Amid Oil Price Volatility
- Market Impact from Oil Prices: The major averages, including the Dow, fell over 400 points as oil prices surged above $100 earlier in the week, reflecting traders' concerns over volatile energy prices and geopolitical tensions in the Middle East.
- IEA's Strategic Release: The International Energy Agency's decision to release approximately 400 million barrels from strategic reserves aims to stabilize energy markets following supply shocks due to conflicts, which could help mitigate extreme oil price fluctuations.
- Inflation Data Reaction: Recent inflation data showed a 0.3% month-over-month increase in the consumer price index and a 2.4% year-over-year rise, both aligning with consensus expectations, indicating persistent inflationary pressures that may influence future monetary policy decisions.
- Escalating Geopolitical Risks: U.S. forces sunk several Iranian ships near the Strait of Hormuz, heightening the fragility of global energy supply routes and contributing to unstable market sentiment, prompting investors to adopt a cautious stance regarding future market movements.
See More
Novo Nordisk Partners with Hims & Hers to Boost Sales
- Market Competition Pressure: Novo Nordisk is losing market share to Eli Lilly in the weight-loss drug sector, which has negatively impacted its sales, although its GLP-1 products still hold significant market potential.
- Strategic Partnership Agreement: The agreement with Hims & Hers allows Novo Nordisk to sell FDA-approved drugs at the same self-pay prices on the platform, which is expected to reduce the appeal of non-FDA-approved versions and boost sales volume.
- Patent Lawsuit Shift: By partnering with Hims & Hers, Novo Nordisk avoids potentially high patent litigation costs while redirecting demand towards its branded medications, thereby enhancing its competitive position in the market.
- Future Product Outlook: Despite a projected revenue decline this year, Novo Nordisk's next-gen GLP-1 drug CagriSema is expected to gain approval within 10 months, with a promising pipeline that could lead to revenue growth over the next three years.
See More
IEA Releases Emergency Oil Reserves Amid Supply Shock
- Emergency Oil Release: The IEA member countries are releasing 400 million barrels of oil in response to the Strait of Hormuz supply shock, with the U.S. contributing 172 million barrels, which may increase household expenses as oil prices rally again.
- Market Reaction: Stock futures are lower this morning due to rising oil prices, reflecting market concerns about the ongoing Iran conflict, and until there is evidence of resolution, the risk of elevated oil prices remains.
- Layoffs and Investment: Atlassian announced a 10% workforce reduction, equating to about 1,600 employees, with the CEO stating this will help self-fund further investments in AI and enterprise sales, highlighting challenges in the traditional software model.
- Private Fund Restrictions: Morgan Stanley and Cliffwater have restricted withdrawals on private credit funds, with Morgan Stanley fulfilling less than half of an 11% redemption request on an $8 billion fund, indicating liquidity issues in the private credit market.
See More
Key Megatrends Remain Relevant: 3 Growth Stocks to Watch Over the Next Decade
Megatrends in Society: Megatrends are long-term shifts that significantly impact various aspects of society, with technology, particularly the internet and smartphones, being prime examples. Current megatrends include advancements in artificial intelligence, aging populations, and the demand for medical treatments.
Investment Opportunities: Companies like Eli Lilly, recognized for their leadership in GLP-1 drugs, and others in diabetes and obesity treatments are positioned to benefit from rising healthcare costs. These firms are seen as potential long-term investments for patient investors.
Clean Energy Demand: The clean energy megatrend is expected to drive significant investments in the coming decades, with companies like First Solar positioned to capitalize on the growing demand for renewable energy solutions, particularly in solar technology.
Stock Recommendations: Analysts have identified five stocks that are recommended for investment, emphasizing their potential for growth in the current market environment, despite recent volatility in the solar sector.
See More
Abivax Denies AstraZeneca Acquisition Talks
- Acquisition Rumor Denial: Abivax has denied media reports claiming that AstraZeneca was in talks to acquire the company, despite the report stating that AstraZeneca had exclusive access to Abivax's data since February and had until March 23 to formalize an offer.
- Stock Price Fluctuation: Following the report, Abivax's shares surged by as much as 15%, but ultimately closed about 4% higher, indicating a cautious market reaction to the acquisition rumors.
- Potential Acquisition Interest: Analysts suggest that Abivax's immunology and inflammation drug obefazimod could attract large pharmaceutical companies for acquisition, especially after its strong performance in last year's late-stage trials, enhancing its strategic value.
- Competitor Attention: In addition to AstraZeneca, Eli Lilly has also been rumored to be in talks with Abivax regarding a potential acquisition, although both companies have declined to comment, reflecting strong market interest in Abivax.
See More
Midday Stock Highlights: Notable Movements in Multiple Stocks
- Market Decline: Mercado Libre's shares fell over 6% after JPMorgan downgraded its rating from overweight to neutral, citing increased competition and prolonged margin pressures, with the price target cut from $2,650 to $2,100, indicating concerns about future profitability.
- Cruise Industry Pressure: Shares of Royal Caribbean and Carnival dropped 5% and 6%, respectively, as oil prices surged past $100 per barrel, with fuel being one of the largest operating expenses for cruise operators, potentially impacting their profitability.
- Energy Stocks Rise: Constellation Energy and Vistra saw their shares increase by 2% following the Department of Energy's announcement of a plan to leverage existing nuclear energy infrastructure for increased power generation, highlighting the strategic importance of nuclear energy for future growth.
- Pet Health Surge: Petco Health and Wellness shares surged nearly 30% after the company indicated a potential return to sales growth, guiding for full-year revenue growth between flat and 1.5%, exceeding market expectations and reflecting confidence in its business recovery.
See More
Major Averages Decline Amid Oil Price Volatility
- Market Impact from Oil Prices: The major averages, including the Dow, fell over 400 points as oil prices surged above $100 earlier in the week, reflecting traders' concerns over volatile energy prices and geopolitical tensions in the Middle East.
- IEA's Strategic Release: The International Energy Agency's decision to release approximately 400 million barrels from strategic reserves aims to stabilize energy markets following supply shocks due to conflicts, which could help mitigate extreme oil price fluctuations.
- Inflation Data Reaction: Recent inflation data showed a 0.3% month-over-month increase in the consumer price index and a 2.4% year-over-year rise, both aligning with consensus expectations, indicating persistent inflationary pressures that may influence future monetary policy decisions.
- Escalating Geopolitical Risks: U.S. forces sunk several Iranian ships near the Strait of Hormuz, heightening the fragility of global energy supply routes and contributing to unstable market sentiment, prompting investors to adopt a cautious stance regarding future market movements.
See More
Novo Nordisk Partners with Hims & Hers to Boost Sales
- Market Competition Pressure: Novo Nordisk is losing market share to Eli Lilly in the weight-loss drug sector, which has negatively impacted its sales, although its GLP-1 products still hold significant market potential.
- Strategic Partnership Agreement: The agreement with Hims & Hers allows Novo Nordisk to sell FDA-approved drugs at the same self-pay prices on the platform, which is expected to reduce the appeal of non-FDA-approved versions and boost sales volume.
- Patent Lawsuit Shift: By partnering with Hims & Hers, Novo Nordisk avoids potentially high patent litigation costs while redirecting demand towards its branded medications, thereby enhancing its competitive position in the market.
- Future Product Outlook: Despite a projected revenue decline this year, Novo Nordisk's next-gen GLP-1 drug CagriSema is expected to gain approval within 10 months, with a promising pipeline that could lead to revenue growth over the next three years.
See More
IEA Releases Emergency Oil Reserves Amid Supply Shock
- Emergency Oil Release: The IEA member countries are releasing 400 million barrels of oil in response to the Strait of Hormuz supply shock, with the U.S. contributing 172 million barrels, which may increase household expenses as oil prices rally again.
- Market Reaction: Stock futures are lower this morning due to rising oil prices, reflecting market concerns about the ongoing Iran conflict, and until there is evidence of resolution, the risk of elevated oil prices remains.
- Layoffs and Investment: Atlassian announced a 10% workforce reduction, equating to about 1,600 employees, with the CEO stating this will help self-fund further investments in AI and enterprise sales, highlighting challenges in the traditional software model.
- Private Fund Restrictions: Morgan Stanley and Cliffwater have restricted withdrawals on private credit funds, with Morgan Stanley fulfilling less than half of an 11% redemption request on an $8 billion fund, indicating liquidity issues in the private credit market.
See More
Key Megatrends Remain Relevant: 3 Growth Stocks to Watch Over the Next Decade
Megatrends in Society: Megatrends are long-term shifts that significantly impact various aspects of society, with technology, particularly the internet and smartphones, being prime examples. Current megatrends include advancements in artificial intelligence, aging populations, and the demand for medical treatments.
Investment Opportunities: Companies like Eli Lilly, recognized for their leadership in GLP-1 drugs, and others in diabetes and obesity treatments are positioned to benefit from rising healthcare costs. These firms are seen as potential long-term investments for patient investors.
Clean Energy Demand: The clean energy megatrend is expected to drive significant investments in the coming decades, with companies like First Solar positioned to capitalize on the growing demand for renewable energy solutions, particularly in solar technology.
Stock Recommendations: Analysts have identified five stocks that are recommended for investment, emphasizing their potential for growth in the current market environment, despite recent volatility in the solar sector.
See More
